20 December, 2018
L&L advised the promoters of Symbiotec Pharmalab and the Company, which is a one of the largest companies in steroids-hormones globally and a leading active pharmaceutical ingredient (API) manufacturer, in a complete buyout of stake of the existing PE investor Actis, by two PE funds, Motilal Oswal Private Equity and Invascent and a further committed primary investment by the funds in the Company.
The L&L team was led by Partner William Vivian John along with Managing Associate Deepak Kumar and Associate Tanaya Sanyal.
